Please ensure Javascript is enabled for purposes of website accessibility

Revolutionizing the Way the Body Responds to Injury

Xequel’s proprietary aCT1 peptide technology platform has extensive preclinical and clinical research data to support multiple unique applications and formulations across therapeutic areas. We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury.

Preclinical

Phase 1

Phase 2

Phase 3

Dermatology

Cutaneous Radiation Injury (CRI)

Orphan Drug Designation Granted

Radiation Dermatitis (RD)

Ophthalmology

Persistent Corneal Epithelial Defects (PCED)

Orphan Drug Designation Pending

Recurrent Corneal Erosions (RCE)

Diabetic
Retinopathy

Pulmonology

Acute
Lung Injury
(ALI)

Acute Respiratory Distress Syndrome (ARDS)

Revolutionizing the Way the Body Responds to Injury

Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology facilitates healing as it stabilizes gap and tight junctions to normalize cell-to-cell signaling, control the flow of fluid within tissues, and reduce harmful inflammation.

Dermatology

Granexin® Gel

Learn More

Ophthalmology

iNexin Ophthalmic Solution

Learn More

Pulmonology

Aerosolized aCT1

Learn More

Contact us for collaborations or partnership opportunities.